Thus, Egr-1-targeting DNAzymes are involved in the initiation and progression of pulmonary vascular remodeling in flow-related pulmonary hypertension and could serve as a potential target for PAH therapy in the future (116). Here, EGR1 is linked to pulmonary arterial hypertension.